Ranibizumab in neovascular age-related macular degeneration
By K. Eng, P. Kertes. Clinical Interventions in Aging, 2006
2,830 citations recorded by the source corpus.
Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF). While other therapies have demonstrated some ability to reduce the risk of losing vision from neovascular AMD, most patients continue to lose some degree of central visual acuity. There is growing evidence that intravitreal administration of ranibizumab and bevacizumab is effective in significantly improving the visual acuity in patients with neovascular age-related macular degeneration.
Subfields: Ophthalmology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/f76379eb3228a933d252eb46b3bd6038d06ee3d8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Ophthalmology
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. (2009, result): “The final VA outcomes in the PrONTO Study were comparable with the results from the phase III clinical trials.(1,2) The PrONTO outcomes were achieved even though there was a dosing error in the first 18 patients enrolled in the study who received an initial 0.”
- Retinal Imaging and Image Analysis (2010, neutral): “With the advent of the anti-VEGF agents ranibizumab and bevacizumab, it has become clear that outer retinal and subretinal fluid is the main indicator of a need for anti-VEGF retreatment [21], [65]–[67].”
- Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. (2008, methodology): “It is ossible that the return of retinal edema in at least some ubjects contributed to the decline in VA, on average, etween months three and 12, in contrast to the patients n the two pivotal ranibizumab trials.(1,2) Also, in the present tudy there was no benefit demonstrated in the percentage mprov”
- Detection of age-related macular degeneration via deep learning (2016, background): “Recent clinical trials have shown that intraocular injections of anti-VEGF agents can significantly reduce the risk of vision loss when compared to no treatment, laser photocoagulation, or photodynamic therapy with verteporfin.(2-4) Furthermore, the better the visual acuity at the start of anti-VEGF”
- Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. (2012, neutral): “5 mg ranibizumab, a humanized onoclonal antibody fragment that blocks VEGF, not nly prevent vision loss in most patients but also lead to ignificant visual gain in approximately one-third.(7,8) The isk of rare but serious adverse events resulting from the ntravitreal procedure, together with the sig”
- Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. (2010, methodology): “Injection procedures were identical to those previously described.(19,20) Briefly, topical anesthetic drops were given, a lid speculum was inserted, and after subconjunctival injection of 2% lidocaine and cleaning of the injection site with 5% povidone iodine, a 30-gauge needle was inserted through ”
- Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). (2013, methodology): “Protocol designs for the MARINA and ANCHOR trials have been described previously.(7,8) A total of 233 patients in the ANCHOR trial and 415 patients in the MARINA trial who were randomized to ranibizumab treatment completed their respective studies.”
- Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. (2014, positive): “Neovascularization in AMD (ANCHOR) and the Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA), showed clear superiority of monthly intravitreal ranibizumab administration compared with sham or with the previous gold standard, photodynami”